Related Experiment Video
Updated: Jun 9, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Early clinical recovery in STEMI cardiogenic shock: insights from the DanGer shock trial
Rasmus Paulin Beske1, Anika Klein1, Lisette Okkels Jensen2,3
1Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark.
Aims:
The DanGer Shock trial demonstrated a mortality benefit with routine use of a microaxial flow pump (mAFP) in ST-elevation acute myocardial infarction complicated by cardiogenic shock (STEMI-CS), but at a cost of more complications. Routine use of a mAFP may, however, expose some patients to unnecessary risk, underscoring the need to identify those who stabilize rapidly and are less likely to derive benefit from device therapy.
Methods And Results:
This post hoc exploratory analysis of the DanGer Shock trial, which randomized STEMI-CS patients to mAFP plus standard care (SoC) or SoC alone, defined 'Fast Recovery' as cardiac intensive care unit (CICU) discharge alive within 3 days of randomization. Baseline variables available at catheterization lab admission associated with 'Fast Recovery' in the SoC arm were identified. Among 355 patients (SoC 176; mAFP 179), 'Fast Recovery' occurred in 29% of the SoC group vs. 15% of the mAFP group. Early CICU discharge favoured SoC through day 3 (HR 2.27, 95% CI 1.48-3.49), with no difference thereafter. Median CICU stay beyond day 3 was 13 days (SoC) vs. 12 days (mAFP), and 94 deaths occurred by day 3 (29% SoC; 24% mAFP). Compared with patients with longer CICU stays, 'Fast Recovery' patients required less inotropic support (44% vs. 85%) and mechanical ventilation (35% vs. 82%) and had lower 180-day mortality (9% vs. 46%, P < 0.001). In the SoC arm, 'Fast Recovery' was associated with lower age, initial higher LVEF, lower heart rate, and lower lactate. Model discrimination was modest (AUROC optimism-corrected 0.74).
Conclusion:
The DanGer Shock trial showed a survival benefit of mAFP use in STEMI-CS, yet about one-third of SoC patients experienced rapid haemodynamic recovery. These 'Fast Recovery' patients were characterized by higher LVEF, younger age, and lower lactate, however discrimination between patients with and without rapid recovery was modest. Distinguishing patients who will recover rapidly remains challenging and warrants further investigation.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Cardiopulmonary Resuscitation IV: Pharmacological Management

